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Abstract
Background: We have previously reported using two-step cluster analysis to classify myasthenia gravis (MG)
patients into the following five subtypes: ocular MG; thymoma-associated MG; MG with thymic hyperplasia;
anti-acetylcholine receptor antibody (AChR-Ab)-negative MG; and AChR-Ab-positive MG without thymic
abnormalities. The objectives of the present study were to examine the reproducibility of this five-subtype
classification using a new data set of MG patients and to identify additional characteristics of these subtypes,
particularly in regard to response to treatment.
Methods: A total of 923 consecutive MG patients underwent two-step cluster analysis for the classification of
subtypes. The variables used for classification were sex, age of onset, disease duration, presence of thymoma or
thymic hyperplasia, positivity for AChR-Ab or anti–muscle-specific tyrosine kinase antibody, positivity for other
concurrent autoantibodies, and disease condition at worst and current. The period from the start of treatment
until the achievement of minimal manifestation status (early-stage response) was determined and then compared
between subtypes using Kaplan-Meier analysis and the log-rank test. In addition, between subtypes, the rate of
the number of patients who maintained minimal manifestations during the study period/that of patients who
only achieved the status once (stability of improved status) was compared.
Results: As a result of two-step cluster analysis, 923 MG patients were classified into five subtypes as follows:
ocular MG (AChR-Ab-positivity, 77%; histogram of onset age, skewed to older age); thymoma-associated MG (100%;
normal distribution); MG with thymic hyperplasia (89%; skewed to younger age); AChR-Ab-negative MG (0%; normal
distribution); and AChR-Ab-positive MG without thymic abnormalities (100%, skewed to older age). Furthermore,
patients classified as ocular MG showed the best early-stage response to treatment and stability of improved status,
followed by those classified as thymoma-associated MG and AChR-Ab-positive MG without thymic abnormalities; by
contrast, those classified as AChR-Ab-negative MG showed the worst early-stage response to treatment and stability
of improved status.
Conclusions: Differences were seen between the five subtypes in demographic characteristics, clinical severity, and
therapeutic response. Our five-subtype classification approach would be beneficial not only to elucidate disease
subtypes, but also to plan treatment strategies for individual MG patients.
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Background
Myasthenia gravis (MG) is a neurological disorder that
manifests as fatigable and fluctuating weakness of
voluntary muscles, which are mediated by autoanti-
bodies against neuromuscular junction proteins in skel-
etal muscle that impair neuromuscular transmission [1].
MG typically involves the ocular, bulbar, and extremity
muscles, and, in severe cases, respiratory muscles. The
clinical course and outcome in MG are affected by sev-
eral different autoantibodies, thymic abnormalities, onset
age and disease severity, as well as response to treatment
[2–4]. MG is distinguished according to the production
of pathogenic autoantibodies such as anti-acetylcholine
receptor antibody (AChR-Ab) and anti–muscle-specific
tyrosine kinase antibody (MuSK-Ab) [1, 5, 6]. Clinically,
MG is often classified into the following three subtypes
based on thymic abnormalities and onset age: thymoma-
associated MG; early-onset MG (onset age <50 years);
and late-onset MG (onset age ≥50 years) [7]. Further-
more, discrimination is observed in the clinical set-
ting—for example, between ocular and generalized
MG—based on the distribution of symptoms.
Previously, we reported classifying MG into the
following five subtypes using two-step cluster ana-
lysis of a detailed cross-sectional data set of 640
consecutive patients (Japan MG Registry Study
2012): ocular MG; generalized thymoma-associated
MG; generalized MG with thymic hyperplasia; general-
ized AChR-Ab-negative MG; and generalized AChR-Ab-
positive MG without thymic abnormalities [8]. However,
this five-subtype classification approach requires further
confirmation, and its clinical relevance remains to be
established.
Therefore, in 2015, we conducted a larger cross-
sectional survey to obtain clinical parameters from 1,088
consecutive MG patients. In the present study, using this
new data set, we attempted to confirm the reproducibil-
ity of our five-subtype classification approach and to
specify additional characteristics of these five subtypes
with a particular focus on response to treatment in the
clinical setting.
Methods
Patients and clinical factors
This survey was conducted by the Japan MG Regis-
try Study Group, which comprises 13 neurological
centers (Table 1). We evaluated patients with estab-
lished MG between April and July 2015. To avoid
potential bias, we enrolled consecutive patients over
a short duration (4 months). All 1088 of these MG
patients visited our hospitals, provided written in-
formed consent, and underwent analysis. Among
these 1088 patients, 331 (30.4%) were included in
our previous survey in 2012 [8].
The following clinical parameters were obtained for all
patients: sex; age; age at disease onset; duration of dis-
ease; duration of immunotherapy; history of bulbar
symptoms; presence of thymoma or thymic hyperplasia
in thymectomized patients; presence of serum AChR-Ab
or MuSK-Ab; and presence of other non-MG-specific
autoantibodies, such as anti-nuclear antibody, SS-A/SS-
B antibody, TSH-receptor antibody, anti-thyroglobulin/
thyroperoxidase antibody, and rheumatoid factor. In
addition, the current and past disease status and details
of treatment were surveyed for all patients. Clinical se-
verity at the worst condition was determined according
to the classification of the MG Foundation of America
(MGFA) [9], and, in some patients, the MGFA quantita-
tive MG score (QMG) [9, 10] from medical records.
Clinical severity at the current condition was determined
according to QMG and MG Composite (MGC) scores
[11]. Furthermore, all patients completed the Japanese
version of the 15-item Myasthenia Gravis Quality-of-Life
Scale (MG-QOL-15), [12, 13] upon study entry.
Prednisone and prednisolone are the global standard
oral corticosteroids used to treat MG, and prednisolone
is generally used in Japan. Therefore, the current use,
peak dose [mg/day], and duration of prednisolone ≥20 mg/
day were recorded for all patients, as was the use of calcine-
urin inhibitors, azathioprine, plasmapheresis, and intraven-
ous immunoglobulin.
Finally, the courses of current and past MGFA post-
intervention statuses, particularly the time required to
achieve first minimal manifestations (MM) or better sta-
tus lasting more than one month (MM-or-better ≥1 M)
[9], were determined as benchmarks for evaluating
Table 1 Institutions participating in the Japan MG Registry
Study 2015
Department of Neurology, Sapporo Medical University Hospital, Sapporo
Department of Neurology, Hokkaido Medical Center, Sapporo
Department of Neurology, Hanamaki General Hospital, Hanamaki
Department of Neurology, Sendai Medical Center, Sendai
Department of Neurology, Tohoku University Graduate School of
Medicine, Sendai
Chiba Neurology Clinic, Chiba
Department of Neurology, Chiba University School of Medicine, Chiba
Department of Neurology, Tokyo Medical University, Tokyo
Department of Neurology, Toho University Medical Center Oh-hashi
Hospital, Tokyo
Department of Neurology, Tokyo Women's Medical University, Tokyo
Department of Neurology, Kinki University School of Medicine, Osaka
Department of Neurology, Graduate School of Medical Sciences, Kyushu
University, Fukuoka
Department of Neurology and Strokology, Nagasaki University Hospital,
Nagasaki
Abbreviation: MG myasthenia gravis
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response to treatment in each patient. These clinical
data were fully collected from 923 (84.8%) of the 1088
patients.
Two-step cluster analysis
To examine the reproducibility of the five-subtype clas-
sification in the same manner as reported elsewhere [8],
we conducted two-step cluster analysis of the 923 pa-
tients using SPSS Statistics Base 22 software (IBM,
Armonk, NY, USA). To avoid bias beset by the problem
of multicollinearity, current or worst disease status was
handled as a single variable (Table 2). The other vari-
ables evaluated were: sex; age of onset; disease duration;
presence of thymoma; presence of thymic hyperplasia in
thymectomized cases; positivity for AChR-Ab or MuSK-
Ab; and positivity for other concurrent autoantibodies
(Table 2).
Early-stage response to treatment and stability of
improved status in each of the five subtypes
Early-stage response to treatment
The time (months) from the start of the immunotherapy
until achieving first MM-or-better ≥1 M was determined
from medical records and compared between the five
subtypes using Kaplan-Meier analysis and the log-rank
test with the Cochran-Mantel-Haenszel procedure. The
time required to achieve first MM-or-better ≥1 M in
50% of patients was also compared among subtypes.
Stability of improved status of MM-or-better ≥1 M
As an indicator of stability of improved status, the rate
of the number of patients who maintained minimal
manifestations in the 2015 survey/that of patients who
achieved the status at least once was calculated and
compared among the five subtypes.
Statistical analysis
All statistical analyses were performed using SPSS
Statistics Base 22 software (IBM) and MATLAB R2015a
(MathWorks, Natick, MA, USA). All continuous data




Based on the results of two-step cluster analyses, all 923
MG patients could be classified into the same five sub-
types described elsewhere [8]: ocular MG; thymoma-
associated MG; MG with thymic hyperplasia; AChR-Ab-
negative MG; and other (in order of predicted import-
ance). Among these five subtypes, the residual patients
group “other” was the largest, and could be defined as
generalized AChR-Ab-positive MG without thymic
abnormalities. These results were demonstrated repeat-
edly with several sets of variables, as shown in Table 2,
which confirmed the high reliability and reproducibility
of the classification system. Although the order among
thymoma-associated MG, MG with thymic hyperplasia,
and AChR-Ab-negative MG was unstable depending on
the variable sets used, the differences in terms of pre-
dicted importance were not large. These results were al-
most identical to those reported elsewhere [8], with only
minor discrepancies in regard to the order of selection
priority (the order in the previous study was as follows:
ocular MG; MG with thymic hyperplasia; AChR-Ab-
negative MG; thymoma-associated MG; and AChR-Ab-
positive MG without thymic abnormalities). In the
present study, the quality of clusterization under each
set of variables, which was estimated using a previously
reported interpretation model [14], was indicated as
“fair” to “good” for all clusters, suggesting that the re-
sults were reasonable.
A total of 111 patients (10.2%) fit two of the five sub-
types (Table 3). These patients were allocated to sole
subtypes according to the separation priority in the two-
step cluster analysis. For example, an ocular MG patient
with thymoma was allocated into ocular MG. Under
this criterion, the percentage of patients assigned to
the five subtypes was as follows: ocular MG, 23.0%;
thymoma-associated MG, 21.5%; MG with thymic
hyperplasia, 12.9%; AChR-Ab-negative MG, 12.1%;
and AChR-Ab-positive MG without thymic abnor-
malities, 30.5% (Table 4).
MG with thymic hyperplasia is only diagnosed for thy-
mectomized patients; therefore, some non-thymectomized
patients with thymic hyperplasia may be assigned as other
subtypes, particularly AChR-Ab-positive MG patients
without thymic abnormalities.
Table 2 Set of variables used in the cluster analyses









One of the following:
The worst MGFA classification
The worst QMG




AChR-Ab anti-acetylcholine receptor antibody, MuSK-Ab anti-muscle specific kinase antibody, MG myasthenia gravis, MGFA MG Foundation of America, QMG quanti-
tative MG, MG-QOL-15 15-item MG-specific quality of life scale, PIS post-intervention status
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Clinical characteristics of each subtype
The clinical characteristics, including current and worst
severity, for each of the five subtypes are shown in
Table 4. The patients with MuSK-Ab were not separated
by two-step cluster analysis because the number is not
great enough for statistical evaluation. However, MG pa-
tients with MuSK-Ab showed a distinct clinical mani-
festation and therapy responsiveness reflecting the
unique pathological mechanism [15]. Therefore, details
of MG patients with MuSK-Ab (n = 22) are individually
described next to SNMG patients in Table 4. The per-
centage of females was significantly higher among MG





Ocular MG and thymoma-associated MG 32 (2.9%) Ocular MG
Ocular MG and AChR-Ab-negative MG 56 (5.1%) Ocular MG
Ocular MG and MG with thymic hyperplasia 8 (0.7%) Ocular MG
MG with thymic hyperplasia and AChR-Ab-
negative MG
14 (1.3%) THMG
Thymoma-associated MG and AChR-Ab-
negative MG
1 (0.09%) TAMG
Values within the parentheses show the percentages of the total of 1,088 patients
AChR-Ab anti-acetylcholine receptor antibody, MG myasthenia gravis














Patients (n) 250 234 140 132 (22) 332 1088
Female,% 52.0 67.5 81.4* 81.1* (81.8) 61.1 65.4
















77.2 99.6 89.4 0.0 (0.0) 100.0 81.3
MuSK-Ab-
positivity,%
0.0% 0.0% 0.0% 20.6% (100.0%) 0.0% 2.1%
Thymectomy,% 23.6%* 97.4%* 100.0%* 12.1%* (9.1%) 35.8%* 51.7%




I,% 100% 0.0% 0.0% 0.0% (0.0%) 0.0% 23.0%
II,% 0.0% 44.0% 52.9% 59.1% (45.5%) 64.8% 43.2%
III,% 0.0% 27.8% 30.7% 28.0% (13.6%) 20.5% 19.6%
IV,% 0.0% 7.7% 7.9% 4.5% (9.1%) 4.2% 4.5%
V,% 0.0% 20.5% 8.6% 8.3% (31.8%) 10.5% 9.7%
Rate of MGFA >
III,%
0.0%* 56.0%* 47.1% 40.9% (54.5%) 35.2% 33.8%
QMG score
(n = 922)





15.8 ± 5.8, 15.0a
(n = 107)
14.7 ± 7.2, 13.0
(n = 114)
18.1 ± 9.7, 15.5
(n = 20)




Current disease condition (mean ± SD, median)
QMG score
(n = 923)
4.2 ± 2.8, 4.0a
(n = 208)
6.8 ± 4.8, 6.0
(n = 198)
7.8 ± 5.5, 7.0
(n = 125)
8.4 ± 5.4, 8.0
(n = 106)
(8.3 ± 6.4, 7.0)
(n = 20)
7.2 ± 4.8, 6.0
(n = 286)
6.6 ± 4.8, 6.0
MGC score
(n = 923)
1.9 ± 2.5, 1.0a
(n = 208)
4.5 ± 5.4, 3.0
(n = 198)
5.4 ± 5.7, 3.0
(n = 125)
6.5 ± 6.2, 5.0a
(n = 106)
(6.2 ± 7.0, 4.5)
(n = 20)
4.2 ± 4.6, 3.0
(n = 286)
4.1 ± 5.0, 3.0
MG-QOL-15
(n = 923)

















All continuous data are expressed as the mean ± standard deviation (SD) and the median
AChR-Ab anti-acetylcholine receptor antibody, MG myasthenia gravis, MGC MG composite scale, MGFA MG Foundation of America, MG-QOL-15 15-item MG-specific
quality of life scale, MuSK-Ab-positive MG patients with serum anti-muscle specific kinase (MuSK) autoantibody in AChR-Ab-negative patients, QMG quantitative MG
score, SD standard deviation
*p < 0.0001, chi-square test (compared to the others), †p < 0.0001, Mann–Whitney U test
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with thymic hyperplasia and AChR-Ab-negative MG
patients compared with the other three subtypes (p <
0.0001, chi-square test). Onset age was significantly
younger in MG with thymic hyperplasia and AChR-
Ab-negative MG patients (p < 0.0001, Mann–Whitney
U test) and older in ocular MG and AChR-Ab-
positive MG patients without thymic abnormalities
(p < 0.0001, Mann–Whitney U test).
Severity at the worst condition (MGFA classification
and QMG) was significantly higher in thymoma-
associated MG patients (p < 0.0001, Mann–Whitney U
test). Patients with MuSK-Ab also showed worst severity
at the same level as thymoma-associated MG patients,
although this result was not statistically significant be-
cause of the small number of patients. The severity
scales (QMG and MGC), and a QOL scale (MG-QOL-
15) scores in the present survey were generally worse, al-
though not statistically significant, in MG with thymic
hyperplasia and AChR-Ab-negative MG patients, both of
which primarily comprise females with younger onset
ages. On the other hand, as a matter of course, ocular
MG patients showed much lower clinical severity in all
batteries at both current and worst conditions (p <
0.0001, Mann–Whitney U test).
Onset age histograms of the five subtypes
Histograms of the onset age for each of the five subtypes
are shown in Fig. 1a. These histograms were converted
into approximate curves (sixth-order polynomial ap-
proximations) and superimposed in Fig. 1b. The peak
ages of the histogram were 60–64 years in ocular MG,
25–29 years in MG with thymic hyperplasia, 35–39 years
in AChR-Ab-negative MG, 50–54 years in thymoma-
associated MG, and 65–69 years in AChR-Ab-positive
MG without thymic abnormalities. The histogram was
skewed toward younger onset age in MG with thymic
hyperplasia and toward older onset age in ocular MG
and AChR-Ab-positive MG without thymic abnormal-
ities. Regarding patients with MuSK-Ab (n = 22), the
mean ± SD onset age was 38.6 ± 15.3 (median, 42.0 years),
and the ratio of females was 81.8%; however, neither of
these findings was significantly different from other
AChR-Ab-negative MG patients.
Early-stage response to treatment and stability of
improved status among the five subtypes
Details of past immunotherapy for each of the five sub-
types are shown at the top of Table 5.
Early-stage response to treatment (first achievement of MM-
or-better ≥1 M)
As shown in the middle of Table 5, the rate of the pa-
tients achieving MM-or-better ≥1 M at least once was
significantly higher for ocular MG (p < 0.001, chi-square
test) and significantly lower for AChR-Ab-negative MG
(p < 0.001, chi-square test).
Kaplan-Meier curves for the time to first achieve MM-
or-better ≥1 M in each of the five subtypes up to 10 years
from initiating immunotherapy are shown in Fig. 2a.
The time to first achieve MM-or-better ≥1 M was sig-
nificantly different among the five subtypes (p < 0.0001;
generalized Wilcoxon test and log-rank test). Significant
differences were observed between all pairs of two sub-
types (p < 0.01 for all pairs; generalized Wilcoxon test)
except MG with thymic hyperplasia and AChR-Ab-
negative MG (p ≥ 0.10). Patients with ocular MG showed
the best early-stage response to treatment compared
with others (p < 0.0001; log-rank test, p < 0.001; chi-
square test). The time required to achieve MM-or-better
≥1 M in 50% of the patients was significantly longer in
MG with thymic hyperplasia and AChR-Ab-negative
MG compared with ocular MG, thymoma-associated
MG, and AChR-Ab-positive MG without thymic abnor-
malities (p < 0.0001, log-rank test; middle of Table 5).
For comparison, Kaplan-Meier curves for the time to
first achieve MM-or-better ≥1 M in early-onset, late-
onset, and thymoma-associated MG (three-type classifi-
cation) are shown in Fig. 2b. Significant differences were
observed between early- and late-onset MG (p < 0.01)
and between early-onset and thymoma-associated MG
(p < 0.01); however, no significant differences were found
between late-onset and thymoma-associated MG (p ≥
0.10).
Stability of improved status
The rates of patients with MM-or-better status during
the survey and stability of improved status are shown in
the bottom of Table 5. Stability of improved status was
significantly better in ocular MG compared with other
subtypes (p < 0.0001; chi-square test); however, no sig-
nificant differences were observed among subtypes other
than ocular MG (p ≥ 0.10 for all pairs, excluding ocular
MG; chi-square test).
Discussion
The present analyses based on several sets of variables
classified 923 MG patients into the same five following
subtypes with the same characteristics of the onset-age
histograms as reported in our previous study [8]: ocular
MG (AChR-Ab-positivity, 77%; histogram of onset age,
skewed to older age); thymoma-associated MG (100%;
normal distribution); MG with thymic hyperplasia (89%;
skewed to younger age); AChR-Ab-negative MG (0%;
normal distribution); and AChR-Ab-positive MG with-
out thymic abnormalities (100%, skewed to older age).
The results from the two different samples demonstrated
high reproducibility, which suggests the reliability of our
five-subtype classification method. In the process of
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Fig. 1 (See legend on next page.)
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analyses, two points were suggested. First, discrimination
between ocular and generalized MG is more principal
than that according to onset age, thymus pathology or
AChR-Ab-positivity. Second, AChR-Ab-negative MG
shows normal distribution of onset age not fitting dis-
crimination based on onset age. Therefore, it is probably
better to adopt the often-used three-type classification
(early-onset, late-onset and thymoma-associated MG)
for generalized and AChR-Ab-positive phenotypes.
Consistently, in our five-subtype classification, MG with
thymic hyperplasia (with early-onset age), AChR-Ab-
positive MG without thymic abnormalities (with late-
onset age) and thymoma-associated MG were general-
ized and AChR-Ab-positive phenotypes.
In fact, these results of our classification statistically
performed are consistent with a recently reported classi-
fication of MG by Gilhus et al. [16, 17], which included
the following classifications: early-onset MG; late-onset
MG; thymoma-associated MG; MuSK-Ab positive MG;
lipoprotein-related protein 4 (LRP4)-Ab positive MG;
seronegative MG; and ocular MG. In addition, they com-
mented that early- and late-onset MG should be
distinguished according to onset age only for patients
having generalized symptoms and AChR-Ab. In the
present study, because of their small numbers, MuSK-
Ab-positive MG patients were not separated, and LRP4-
Ab positivity was not systematically determined; though
MG patients with MuSK-Ab or LRP 4-Ab have a distinct
clinical manifestation and a unique pathological mech-
anism [15].
Ocular MG was found to have unique characteristics
such as having a higher onset age, predominantly
affecting males, and having an ocular muscle-specific
pathogenesis [18], which may be related to the aging-
associated susceptibility of ocular muscles to antibodies
against the neuromuscular junction. Given that response
to treatment and stability of improved status were sub-
stantially better in ocular MG compared with the other
four subtypes, it seems reasonable to conclude that ocu-
lar MG should be treated as a distinct subgroup of MG
in the clinical setting.
Among the four generalized subtypes in the present
classification method, both early-stage response to treat-
ment and stability of improved status were worst in















Past immunotherapy (n = 923)








23.7 ± 20.2, 20.0 21.5 ± 19.3,
15.0




13.0 ± 27.3, 6.0† 3.8 ± 7.0, 0.0 7.2 ± 9.5, 4.0 8.2 ± 17.0, 2.0 7.9 ± 19.3,
1.0
CNIs,% 24.0%* 68.2%* 54.0% 67.4% (72.7%) 58.1% 52.9%
PP,% 2.0%* 48.1%* 22.1% 46.0%* (54.5%) 37.2% 27.3%
IVIG,% 6.1%* 36.1% 29.9% 42.5%* (27.3%) 24.7% 15.0%
Initial response to treatment (n = 923, see Fig. 2a)
Achievement of MM-or-better
once,%
79.8%* 73.5% 66.1% 56.2%* (75.0%) 67.8% 70.2%
Months to achieve MM-or-better
in 50% of patients
4.0‡ 8.0 18.0‡ 31.0‡ (7.0) 6.0 8.0
Stability of improved status (n = 923)
MM-or-better at present,% 74.0%* 58.1% 49.6% 39.6%* (55.0%) 55.4% 57.6%
Maintaining rate of MM-or-
better, %
92.7%* 79.0% 75.0% 70.5% (73.3%) 81.7% 82.1%
All continuous data are expressed as the mean ± standard deviation (SD) and the median
CNIs calcineurin inhibitors, EAT early aggressive therapy, IVIG intravenous immunoglobulin, M months, MG myasthenia gravis, MM-or-better ≥1M minimal
manifestation or better status lasting more than one month, MuSK-Ab-positive MG patients with serum anti-muscle specific kinase (MuSK) autoantibody in AChR-
Ab-negative patients, PP plasmapheresis, PSL prednisolone, SD standard deviation
*p < 0.0001, chi-square test,†p < 0.0001, Mann–Whitney U test,‡p < 0.0001, log-rank test
(See figure on previous page.)
Fig. 1 Histograms and approximate curves for onset age in the five MG subtypes. a Histograms for ocular MG, generalized thymoma-associated
MG (TAMG), generalized MG with thymic hyperplasia (THMG), generalized AChR-Ab-negative MG (SNMG) and generalized AChR-Ab-positive MG
without thymic abnormalities (SPMG). b Superimposed approximate curves for the five subtypes regarding the distribution of onset age. The
vertical broken line indicates the cutoff onset age of 50 years between early- and late-onset MG. MG, myasthenia gravis
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AChR-Ab-negative MG, although symptoms at the time
the condition was at its worst were not particularly se-
vere. Patients with MuSK-Ab-positive MG showed better
results despite having more severe worst conditions,
which suggests that AChR-Ab-negative MG, excluding
MuSK-Ab-positive MG, is distinct from other general-
ized MG subtypes from the perspective of response to
therapy. Overall, as shown in Fig. 2a, each of the five
present subtypes showed different levels of response to
treatment, whereas such differences in the three
commonly used subtypes (early-onset, late-onset, and
thymoma-associated MG) remain somewhat unclear
(Fig. 2b). It would be more helpful in the clinical setting
to elucidate the levels of response to some types of
Fig. 2 Kaplan-Meier curves for the first achievement of MM-or-better ≥1 M in the five subtypes and those in the three subtypes of early-onset,
late-onset, and thymoma-associated MG. a Kaplan-Meier curves for the five subtypes [ocular MG, generalized thymoma-associated MG (TAMG),
generalized MG with thymic hyperplasia (THMG), generalized AChR-Ab-negative MG (SNMG) and generalized AChR-Ab-positive MG without
thymic abnormalities (SPMG)]. b Kaplan-Meier curves for the three subtypes of early-onset, late-onset, and thymoma-associated MG. MM, minimal
manifestations; MG, myasthenia gravis
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medication or therapy (e.g. corticosteroids, non-steroid
immunosuppressants, intravenous immunoglobulin and
plasmapheresis) in the five subtypes. However, it was dif-
ficult to analyze such response levels, as plural treatment
agents and methods were employed simultaneously in
most of individual patients. We are now analyzing the
response levels according to patterns of immune treat-
ment (treatment strategies) in generalized MG patients
[19]. Such analysis should be performed also for the
present five subtypes, but could not be addressed in the
present report.
The present study did have some limitations. First, 331
(30.4%) of the 1,088 patients were included in our previ-
ous survey in 2012, which might have affected the repro-
ducibility of the present five-subtype classification.
Second, almost all of the MG patients in our database
are Japanese; therefore, a race/ethnicity bias may have
affected the results. Finally, some MG patients with
thymic hyperplasia might have been classified as AChR-
Ab-positive MG without thymic abnormalities because
the diagnosis of thymic hyperplasia is made based on the
results of pathological examinations after thymectomy.
However, the frequency of thymectomy for MG patients
without thymoma has been decreasing [20]; therefore,
some of the AChR-Ab-positive MG patients with youn-
ger onset age who had not undergone thymectomy
could have had thymic hyperplasia.
Conclusion
The results of the present study suggest that MG pa-
tients can be classified into the following five subtypes
in order of priority: ocular MG; thymoma-associated
MG; MG with thymic hyperplasia; AChR-Ab-negative
MG; and AChR-Ab-positive MG without thymic abnor-
malities. All MG patients can be allocated to one of the
subtypes based on the results of routine examinations.
These five subtypes were shown to have characteristic
demographic characteristics, clinical severity, and thera-
peutic responses. Therefore, our five-subtype classifica-
tion method is expected to be beneficial not only for
elucidating disease types, but also for planning proper
treatment for individual patients.
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